Version 1
: Received: 4 May 2024 / Approved: 6 May 2024 / Online: 6 May 2024 (04:52:05 CEST)
How to cite:
Saleh, Y.; Abu Hejleh, T.; Abdelrahim, M.; Shamseddine, A.; Chehade, L.; Alawabdeh, T.; Mohamad, I.; Sammour, M.; Turfa, R. HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Preprints2024, 2024050212. https://doi.org/10.20944/preprints202405.0212.v1
Saleh, Y.; Abu Hejleh, T.; Abdelrahim, M.; Shamseddine, A.; Chehade, L.; Alawabdeh, T.; Mohamad, I.; Sammour, M.; Turfa, R. HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Preprints 2024, 2024050212. https://doi.org/10.20944/preprints202405.0212.v1
Saleh, Y.; Abu Hejleh, T.; Abdelrahim, M.; Shamseddine, A.; Chehade, L.; Alawabdeh, T.; Mohamad, I.; Sammour, M.; Turfa, R. HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Preprints2024, 2024050212. https://doi.org/10.20944/preprints202405.0212.v1
APA Style
Saleh, Y., Abu Hejleh, T., Abdelrahim, M., Shamseddine, A., Chehade, L., Alawabdeh, T., Mohamad, I., Sammour, M., & Turfa, R. (2024). HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Preprints. https://doi.org/10.20944/preprints202405.0212.v1
Chicago/Turabian Style
Saleh, Y., Mohammad Sammour and Rim Turfa. 2024 "HCC: Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation" Preprints. https://doi.org/10.20944/preprints202405.0212.v1
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths. Classically, liver transplantation (LT) can be curable for HCC tumors within the Milan criteria. Bridging strategies to reduce the dropouts from LT waiting lists or/and to downstage patients who are beyond Milan criteria are widely utilized. We conducted a literature-based review to evaluate the role of systemic therapies as a bridging treatment to liver transplantation (LT) in HCC patients. Tyrosine Kinase Inhibitors (TKIs) can be used as a bridging systemic therapy to LT in patients with contraindication to locoregional liver-directed therapies. Immune Checkpoint Inhibitors (ICIs) treatment can be utilized either as a monotherapy or as a combination therapy with Bevacizumab or TKIs prior to LT. Acute rejection post liver transplantation is a concern in the context of ICIs treatment. Thus, a safe ICI washout period before LT and cautious post-LT immunosuppression strategies are required to reduce post-LT rejections and to optimize clinical outcomes. Nevertheless, prospective clinical trials are needed to establish definitive conclusions about the utility of systemic therapy as a bridging modality prior to LT in HCC patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
